| Title |
Novel Bruton's tyrosine kinase inhibitors currently in development
|
|---|---|
| Published in |
OncoTargets and therapy, March 2013
|
| DOI | 10.2147/ott.s33732 |
| Pubmed ID | |
| Authors |
Osmond J D’Cruz, Fatih M Uckun |
| Abstract |
Bruton's tyrosine kinase (Btk) is intimately involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells. Btk is overexpressed and constitutively active in several B-lineage lymphoid malignancies. Btk has emerged as a new antiapoptotic molecular target for treatment of B-lineage leukemias and lymphomas. Preclinical and early clinical results indicate that Btk inhibitors may be useful in the treatment of leukemias and lymphomas. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 87 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 33% |
| Student > Master | 11 | 13% |
| Student > Ph. D. Student | 10 | 11% |
| Other | 10 | 11% |
| Student > Bachelor | 5 | 6% |
| Other | 11 | 13% |
| Unknown | 11 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 33 | 38% |
| Medicine and Dentistry | 16 | 18% |
| Chemistry | 8 | 9% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Other | 6 | 7% |
| Unknown | 12 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2024.
All research outputs
#3,452,687
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#116
of 2,967 outputs
Outputs of similar age
#27,566
of 206,591 outputs
Outputs of similar age from OncoTargets and therapy
#3
of 22 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,591 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.